Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYU.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior TherapyPREV STORYAscendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
